Cellectis SA (CLLS) AI Stock Analysis

Compare

931 Followers

CLLS Dividends

Top Page

Cellectis SA

(NASDAQ:CLLS)

57Neutral

Cellectis SA's stock score is influenced by its strong strategic collaborations, notably with AstraZeneca, which enhance its financial stability and extend its cash runway. However, the company's ongoing challenges with profitability and mixed technical signals weigh down the overall score. The positive earnings call sentiment and future clinical trial advancements are significant positives, whereas current valuation metrics and profitability issues are key concerns.

Positive Factors

Clinical Development

Strong demand for trial entry should facilitate enrollment speed for UCART20x22.

Financial Performance

Cellectis reported a quarter-end cash balance of $264M, up from $165M at YE2023.

Strategic Partnership

The AZN collaboration is progressing, initially focused on three programs with an option to expand to ten in total.

Negative Factors

Operational Costs

Cellectis reported a 3Q24 update with opex of $28.8M.

Project Prioritization

UCART123 (AMELI-01 trial) is deprioritized.

Cellectis SA (CLLS) vs. S&P 500 (SPY)

Market Cap

$107.35M

Dividend YieldN/A

Average Volume (3M)598.87K

Price to Earnings (P/E)―

Beta (1Y)3.76

Revenue Growth5397.35%

EPS Growth77.93%

CountryUS

Employees216

SectorHealthcare

Sector Strength64

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.37

Shares Outstanding72,093,636

10 Day Avg. Volume113,010

30 Day Avg. Volume598,866

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)1.90

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$5.50

Price Target Upside276.71% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Cellectis SA Business Overview & Revenue Model

Company DescriptionCellectis SA is a clinical-stage biopharmaceutical company that operates in the field of gene-editing technology. Founded in 1999 and headquartered in Paris, France, the company focuses on developing immunotherapies based on gene-edited allogeneic CAR-T cells for the treatment of cancer. Using its proprietary TALEN technology and electroporation system, Cellectis aims to harness the power of the immune system to target and eradicate cancer cells, offering a potentially transformative approach to cancer treatment.

How the Company Makes MoneyCellectis makes money primarily through strategic partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and potential royalties based on the successful development and commercialization of products stemming from its gene-editing technologies. Additionally, Cellectis may generate revenue by advancing its own proprietary pipeline of CAR-T cell therapies through clinical trials, with the potential of achieving regulatory approvals and subsequent commercialization. The company's business model leverages its intellectual property and technological expertise in gene editing to create value and establish revenue streams from both collaborative and independent development efforts.

Cellectis SA Financial Statement Overview

Summary

Cellectis SA shows promising revenue growth but struggles with profitability and efficiency. The balance sheet reflects moderate leverage but low returns on equity. Despite improved cash flow, the company faces challenges in achieving consistent profitability.

Income Statement

Negative

The company's revenue increased significantly in the TTM, but it operates at a loss with a negative net profit margin. The gross profit margin is healthy, but the EBIT and EBITDA margins are negative, reflecting operational inefficiencies and high expenses relative to revenue.

Balance Sheet

Negative

The debt-to-equity ratio is moderate, showing balanced leverage. However, the company has negative net income, resulting in a negative ROE, which is concerning. The equity ratio indicates a reasonable level of equity financing.

Cash Flow

Neutral

The company has positive operating cash flow and free cash flow in the TTM. This is an improvement from prior periods, but the free cash flow to net income ratio is negative due to persistent net losses, indicating cash flow generation challenges.

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
41.51M	755.00K	19.17M	73.95M	73.95M
	Gross Profit
41.51M	18.00K	17.40M	37.67M	37.67M
	EBIT
-59.55M	-106.63M	-89.67M	-85.44M	-85.44M
	EBITDA
-9.46M	-92.64M	-76.38M	-86.46M	-34.68M
	Net Income Common Stockholders
-36.76M	-101.06M	-98.69M	-86.28M	-72.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
260.31M	203.81M	97.70M	186.13M	268.24M
	Total Assets
383.54M	334.27M	261.22M	382.08M	469.47M
	Total Debt
91.46M	92.85M	82.85M	102.24M	111.30M
	Net Debt
-51.79M	-43.85M	-14.85M	-83.90M	-156.94M
	Total Liabilities
252.51M	249.57M	135.28M	145.60M	160.63M
	Stockholders Equity
131.03M	84.69M	117.97M	221.29M	275.57M
Cash Flow		Free Cash Flow
19.15M	-25.82M	-89.89M	-124.31M	-126.52M
	Operating Cash Flow
22.99M	-24.75M	-87.44M	-104.56M	-80.26M
	Investing Cash Flow
-102.81M	-15.51M	-2.76M	7.28M	-54.34M
	Financing Cash Flow
89.11M	82.86M	1.15M	47.52M	27.32M

Cellectis SA Technical Analysis

Technical Analysis Sentiment

Positive

Last Price1.46

Price Trends

50DMA

1.34

Positive

100DMA

1.54

Negative

200DMA

1.80

Negative

Market Momentum

MACD

0.03

Negative

RSI

59.29

Neutral

STOCH

65.10

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLLS, the sentiment is Positive. The current price of 1.46 is above the 20-day moving average (MA) of 1.32, above the 50-day MA of 1.34, and below the 200-day MA of 1.80, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 59.29 is Neutral, neither overbought nor oversold. The STOCH value of 65.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLLS.

Cellectis SA Risk Analysis

Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the “Tech & Innovation” category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Cellectis SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	57 Neutral	$107.35M	―	-34.08%	―	5397.35%	77.93%
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
NKTX	39 Underperform	$111.76M	―	-31.94%	―	―	30.76%
FDMT	39 Underperform	$157.43M	―	-25.95%	―	―	―
CRBU	34 Underperform	$77.72M	―	-47.99%	―	-71.01%	-14.04%
EDIT	33 Underperform	$130.59M	―	-98.10%	―	-58.64%	-40.05%
VOR	33 Underperform	$87.65M	―	-94.52%	―	―	2.98%

* Healthcare Sector Average

Performance Comparison

CLLS

Cellectis SA

1.46

-1.04

-41.60%

EDIT

Editas Medicine

1.56

-3.79

-70.84%

NKTX

Nkarta

2.18

-4.99

-69.60%

FDMT

4D Molecular Therapeutics

3.42

-20.83

-85.90%

VOR

Vor Biopharma

0.76

-0.98

-56.32%

CRBU

Caribou Biosciences

0.84

-3.01

-78.18%

Cellectis SA Earnings Call Summary

Earnings Call Date: Mar 13, 2025 | % Change Since: 13.18% | Next Earnings Date: May 7, 2025

Earnings Call Sentiment Positive

The earnings call reflected a positive outlook for Cellectis, highlighted by strategic collaborations, strong financial positioning, and advancements in clinical trials. Challenges include ongoing arbitration with Servier and patient enrollment progress, but these are outweighed by the company's achievements.

Highlights

Strategic Collaboration with AstraZeneca

Cellectis announced the start of three research and development programs under its collaboration with AstraZeneca, including allogeneic CAR T for hematological malignancies, solid tumors, and an in vivo gene therapy for a genetic disorder. AstraZeneca also completed an additional equity investment of $140 million in Cellectis.

Financial Stability and Cash Runway

Cellectis drew down the last tranches of a €40 million credit facility with the European Investment Bank and reported that their cash runway allows operations to be funded into mid-2027. As of December 31, 2024, the company had $264 million in cash, cash equivalents, and fixed term deposits, up from $156 million the previous year.

FDA and European Commission Designations

The FDA granted Orphan Drug Designation and Rare Pediatric Disease status to UCART22, and the European Commission granted Orphan Drug Designation for the treatment of relapse or refractory acute lymphoblastic leukemia.

Advancements in Clinical Trials

Cellectis expects to present Phase 1 data for UCART22 and UCART20x22 in 2025, with plans to open Phase 2 studies in Q4 2025. Recruitment for the BALLI-01 study evaluating UCART22 has progressed well.

Positive Financial Performance

Thanks to the AstraZeneca collaboration, $47 million were received up to year-end 2024, including $22 million from development milestones.

Promising Innovation in CAR T Strategies

Cellectis showcased promising CAR T strategies utilizing TALEN gene editing technology, with preclinical data presented at major conferences and publications in scientific journals.

Lowlights

Servier Arbitration

There is ongoing arbitration with Servier, although specific details remain undisclosed.

Challenges in Patient Enrollment

Enrollment for the NATHALI-01 study of UCART20x22 in relapsed or refractory non-Hodgkin's lymphoma continues, but specific challenges or delays in enrollment were not detailed.

Company Guidance

In the recent Cellectis earnings call for fiscal year 2024, the company provided guidance on several key metrics. Cellectis announced that its cash runway is now extended to mid-2027, thanks to an additional equity investment of $140 million from AstraZeneca, which now owns approximately 44% of Cellectis' share capital and 30% of voting rights. The company also reported that it received $47 million under its collaboration with AstraZeneca, including $25 million upfront and $22 million from development milestones. Cellectis' cash, cash equivalents, and financial assets increased to $264 million as of December 31, 2024, compared to $156 million in the previous year. This increase is attributed to the equity investment, $20 million from the European Investment Bank credit facility, and revenue from partnerships, offset by operational expenses. The company expects to present Phase 1 data for UCART22 and UCART20x22 in 2025 and continues to advance its core clinical trials and collaboration with AstraZeneca.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.